Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.
The question is straightforward. Which peptide, Cerebrolysin or Dihexa, delivers better neuroplasticity outcomes when the evidence is weighed carefully? The answer is less clear than marketing materials suggest. Cerebrolysin has decades of human trial data. Dihexa has almost none. That asymmetry shapes everything that follows.
What We Would Want to See
An ideal comparison would include head-to-head human trials. We would want randomized, placebo-controlled studies measuring synaptic density, dendritic branching, cognitive performance, and safety profiles across matched populations. We would want dose-response curves, time-to-effect data, and adverse-event tracking over months or years. We would want functional imaging showing changes in hippocampal volume or cortical connectivity.
We do not have that. Not even close.
What Cerebrolysin Brings: Human Data, Mixed Quality
Cerebrolysin is a porcine-brain-derived peptide mixture containing neurotrophic factors. It has been studied in stroke, traumatic brain injury, and dementia since the 1980s. The evidence base is large but uneven.
In a 2016 Cochrane review published in the Cochrane Database of Systematic Reviews, Ziganshina and colleagues analyzed six trials involving something like 600 patients with vascular dementia. They found no consistent benefit on cognitive outcomes. The authors flagged high risk of bias in most included studies. Evidence quality rated around 1.5 of 3.
Stroke data looks marginally better. A 2017 meta-analysis in CNS Drugs by Bornstein and colleagues pooled data from roughly 1,500 acute ischemic stroke patients. Cerebrolysin groups showed modest improvements in functional independence measures at 90 days, with effect sizes in the neighborhood of 0.2 to 0.3 standard deviations. Not dramatic. The authors noted heterogeneity in dosing, timing, and outcome measures across trials.
Traumatic brain injury studies show similar patterns. A 2018 paper in the Journal of Neurotrauma by Chen and team reported improvements in Glasgow Outcome Scale scores among 120 patients receiving 30 milliliters daily for 10 days. Absolute difference was something like 15 percent better outcomes in the treatment arm. Small sample, open-label design. Evidence quality maybe 2 of 3 at best.
Mechanism: What Cerebrolysin Might Be Doing
Preclinical work suggests Cerebrolysin upregulates brain-derived neurotrophic factor and nerve growth factor signaling. A 2019 study in Restorative Neurology and Neuroscience by Hartbauer and colleagues showed increased synaptic protein expression in rat hippocampus after 14 days of dosing. Dendritic spine density increased by roughly 20 to 30 percent compared to saline controls. Whether this translates to humans remains speculative.
Dosing in human trials typically ranges from 10 to 50 milliliters intravenously, given daily or several times weekly for 10 to 21 days. Oral bioavailability is negligible due to peptide degradation in the gut. Safety profile is relatively clean. Reported adverse events include headache, dizziness, and rare hypersensitivity reactions. No major organ toxicity signals in the published literature.
What Dihexa Brings: Potency Without People
Dihexa is a small synthetic peptide derived from angiotensin IV. It was developed at Washington State University and patented in the early 2010s. The compound binds hepatocyte growth factor and its receptor, c-Met, supposedly amplifying synaptogenic signaling.
Animal data is striking. A 2012 paper in PLOS ONE by McCoy and colleagues reported that Dihexa improved spatial learning in aged rats at doses around 0.5 milligrams per kilogram. Performance on Morris water maze tasks improved by something like 40 to 60 percent relative to controls. Synaptic density in hippocampal CA1 regions increased measurably.
A 2014 follow-up in the same journal by Benoist and team showed similar effects in a scopolamine-induced amnesia model. Dihexa reversed cognitive deficits at doses as low as 0.1 milligrams per kilogram. The authors claimed potency seven orders of magnitude greater than brain-derived neurotrophic factor in vitro. That claim is hard to verify independently.
The Human Data Gap
There are no published human trials for Dihexa. Zero. Not in healthy volunteers, not in patients, not even case reports in peer-reviewed journals. ClinicalTrials.gov shows one Phase I safety study listed in 2015, status unknown, no results posted. That is the entire human evidence base.
This is a 1 of 3 on evidence quality for human use. Maybe 0.5 of 3.
Dosing in online communities ranges from 1 to 10 milligrams orally, extrapolated from rat data using crude allometric scaling. Oral bioavailability is assumed but not measured in humans. Half-life, tissue distribution, metabolic pathways, all unknown. Adverse-event data consists of anecdotal reports: headaches, mood changes, sleep disruption. No formal pharmacovigilance.
What Is Missing in Both Cases
Neither peptide has robust imaging data showing structural brain changes in humans. We do not have serial MRI studies tracking hippocampal volume or cortical thickness. We do not have PET imaging showing receptor occupancy or metabolic shifts. We do not have electrophysiological recordings demonstrating synaptic strengthening.
For Cerebrolysin, we lack dose-optimization studies. Most trials use fixed regimens without exploring whether 15 milliliters might work as well as 50. We lack long-term follow-up. Most studies end at 90 days. Durability of effects is unclear.
For Dihexa, we lack everything. Pharmacokinetics, toxicology, target engagement, clinical efficacy. The compound might be extraordinary. It might also be inert or harmful in humans. We simply do not know.
How to Read the Available Evidence
Cerebrolysin has the advantage of regulatory approval in multiple countries, primarily in Eastern Europe and Asia. That approval reflects some threshold of demonstrated safety and possible efficacy, even if the evidence quality is mixed. The compound has been dosed in thousands of patients without catastrophic safety signals.
Dihexa has the advantage of mechanistic plausibility and dramatic preclinical effects. If the animal data translates, it could be substantially more potent than Cerebrolysin. But translation is a big if. Most CNS compounds fail in human trials. The base rate of success is something like 10 to 15 percent.
Consider the evidence asymmetry carefully. Cerebrolysin has weak-to-moderate human evidence. Dihexa has strong animal evidence and zero human evidence. These are not equivalent positions. One allows cautious inference. The other allows only speculation.
The Honest Answer
If the question is which peptide delivers superior neuroplasticity in humans, the only defensible answer is Cerebrolysin, by default. Not because the evidence is strong. It is not. But because some human evidence beats no human evidence.
Cerebrolysin shows modest, inconsistent benefits in stroke and brain injury populations. Effect sizes are small. Trial quality is often poor. But the compound has been tested in the species that matters. We know it does not cause widespread harm. We know it might help a little, in some contexts, for some people.
Dihexa remains a research chemical in the truest sense. The animal data is tantalizing. The mechanism is interesting. But without human trials, we cannot know if it works, at what dose, or whether it is safe over weeks or months. Extrapolating from rats to humans is guesswork dressed up in milligrams per kilogram.
If you are evaluating these compounds for research purposes, prioritize the one with human data. If you are waiting for a clear winner, wait for Dihexa trials to materialize. Until then, the comparison is between incomplete evidence and absent evidence. That is not a fair fight.
Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.